Pharma News, 2022

The UK’s National Institute of Health and Care Excellence (NICE) has recommended Rhythm Pharmaceuticals’ Imcivree (setmelanotide) for National Health Service (NHS) use in treating obesity linke...

A small international team of researchers has developed a way to synthesize tetrodotoxin (TTX) using far fewer steps than prior methods. 

Biogen has agreed in principle to pay $900 million to settle a whistleblower lawsuit over alleged kickbacks to physicians before the case goes to a jury trial in Boston next week. ...

The European Medicines Agency said Friday that the smallpox vaccine made by Bavarian Nordic should also be authorized against monkeypox, as the outbreak of the once-rare disease continues to sicken...

In children in the US and UK, a sudden increase in the number of cases of severe acute hepatitis of unknown causes (SAHUC) and pediatric acute liver failure was reported between October 2021 and Ma...

British scientists have found a potential treatment for people living with hemophilia B.

VBL Therapeutics’ investigational drug ofra-vec (ofranergene obadenovec; VB-111) failed to show promise in a late-stage study for treatment of platinum-resistant ovarian cancer. ...

Japan’s Health, Labor and Welfare Ministry panel postponed a decision to approve Shionogi’s oral COVID-19 antiviral drug Xocova.

As many Korean pharmaceutical manufacturers are currently attempting to develop new drugs for idiopathic pulmonary fibrosis, Daewoong Pharmaceutical Co., Ltd.'s new medication DWN12088 has been fas...

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved QSYMIA (phentermine and topiramate extended-release capsules) CIV for use in the treatment of obesity in adoles...

The FDA has expanded its approval of Incyte’s Opzelura (ruxolitinib) topical cream to include adult and pediatric patients 12 years and older with nonsegmental vitiligo, a chronic autoimmune dis...

The FDA has approved Azurity Pharmaceuticals’ Zonisade (zonisamide oral suspension) as an adjunctive therapy for the treatment of partial seizures in epilepsy patients aged 16 years and older. ...